NotablePrimary completion moved earlier from Nov 30, 2030 to Nov 2029
Study completion moved earlier from Dec 30, 2030 to Jul 2030
NotablePrimary completion date: Nov 30, 2030 to Nov 2029
Study completion date: Dec 30, 2030 to Jul 2030
NotableEligibility criteria expanded, about 18 words
Interventions modified
Collaborators revised (9)
Publications: 28 to 31
NotableStart date: Aug 1, 2026 to Jan 20, 2027Show 4 more changesShow less
Eligibility criteria expanded, about 2 words
Interventions: Abbott Determine HIV - 1/2 Ag/Ab (Device), Abbott Determine HbsAg 2 (Device), Cepheid GeneXpert HCV Test (Device), Sofosbuvir / Velpatasvir… to Abbott Determine HIV - 1/2 Ag/Ab (Device), Abbott Determine HbsAg 2 (Device), Cepheid GeneXpert HCV Test (Device), Sofosbuvir / Velpatasvir…
Secondary endpoints: details revised at 11 of 20 entries
Publications: details revised at 28 of 28 entries
NotablePrimary endpoint(s) modified
Secondary endpoints revised (20)
v2
Study First Submitted
Notable: the plan changed
Endpoints
Primary
Proportion of participants who complete the Hepatitis C Virus (HCV) care cascade within 24 weeks of study entry in intervention versus Standard of Care (SOC) arm.
Timeframe: 24 weeks from study enrollment
Secondary (20)
Proportion of participants initiating same-visit direct-acting antiviral (DAA) treatment following enrollment (intervention arm only)
Proportion of participants initiating direct-acting antiviral (DAA) therapy within 12 weeks of entry
Proportion of participants initiating direct-acting antiviral (DAA) therapy within 24 weeks of entry
Time from enrollment to treatment initiation
Proportion of participants completing direct-acting antiviral (DAA) therapy within 24 weeks of entry
Show 15 moreShow less
Proportion of participants achieving sustained virologic response (SVR4+) within 60 weeks of entry
Cumulative incidence of HCV reinfection following sustained virologic response (SVR4+) within 60 weeks of entry
Cumulative retreatment following sustained virologic response (SVR4+) or relapse within 60 weeks of entry
Proportion of participants with HCV RNA not detected based on dried blood spot at week 24 and week 60
Proportion of participants who have received any HIV test result within 24 weeks of entry
Proportion of participants who initiate PrEP within 24 weeks of entry
Proportion of participants with HIV who commence direct-acting antiviral (DAA) therapy within 24 weeks of entry
Proportion of participants with HIV not on antiretroviral therapy (ART) at screening who commence ART within 24 weeks of entry
Proportion of participants with HIV on antiretroviral therapy (ART) at screening who remain on ART at week 24 and week 60
Time from enrollment to PrEP initiation
All cause and liver specific hospitalizations through week 60
All cause and liver specific mortality through week 60
On direct-acting antiviral (DAA) treatment serious suspected adverse events leading to discontinuation of sofosbuvir/velpatasvir
Adverse maternal and fetal outcomes for those on direct-acting antiviral (DAA) at any time during pregnancy
Adverse device effects related to study devices
Arms and interventions
Standard of Care (control arm)Active comparator
Participants will complete standard local clinical practice for HCV, HIV, and HBV testing and for initiation of treatment of HCV.
Single-visit POC test & treat (intervention arm)Experimental
Sites randomized to the single-visit point-of-care test (POC) \& treat arm will undergo fingerstick POC HCV RNA, HIV antibody/antigen, and HBsAg and for those with detectable HCV RNA, HCV treatment will be initiated.
Devices: Cepheid GeneXpert HCV Test
Diagnostic tests: INSTI HIV - 1/2 Antibody, bioLytical Laboratories iStatis Hepatitis B Surface Antigen Test